This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RVPHW Reviva Pharmaceuticals (RVPHW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesShort InterestTrendsBuy This Stock About Reviva Pharmaceuticals Stock (NASDAQ:RVPHW) Get Reviva Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0030▼$0.005050-Day Range$0.00▼$0.0452-Week Range$0.00▼$0.18Volume251,039 shsAverage Volume86,037 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage specialty pharmaceutical company committed to developing novel therapies for dermatologic and ophthalmic conditions with high unmet medical need. The company leverages proprietary formulation and drug‐delivery technologies to advance product candidates through preclinical and clinical development, aiming to enhance solubility, stability and bioavailability in topical and ocular applications. Reviva’s pipeline comprises multiple investigational candidates at various stages. Its lead program, RVI-001, is a topical solution designed to treat common plantar warts and is advancing toward late‐stage clinical testing. Additional programs target inflammation‐driven skin disorders and ocular surface diseases, reflecting the company’s strategic focus on conditions with limited approved therapies. Reviva maintains strategic collaborations with contract research and manufacturing organizations to support formulation optimization and scalable production. Headquartered in Palm Beach County, Florida, Reviva Pharmaceuticals conducts its research and development activities primarily in the United States, with clinical trials spanning sites across North America. Since its founding, the company has assembled a team of experts in dermatology, ophthalmology, formulation science and regulatory affairs. Reviva’s common shares trade on the NASDAQ Capital Market under the ticker RVPH, while its warrants trade under the symbol RVPHW.AI Generated. May Contain Errors. Read More Receive RVPHW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVPHW Stock News HeadlinesReviva Pharmaceuticals Holdings (RVPH) price target decreased by 50.79% to 38.15April 29, 2026 | msn.comReviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric IndicationsApril 23, 2026 | markets.businessinsider.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 5 at 1:00 AM | Paradigm Press (Ad)Reviva Pharmaceuticals Holdings (RVPH) price target increased by 14.00% to 77.52April 15, 2026 | msn.comReviva Announces Letter to ShareholdersApril 15, 2026 | finance.yahoo.comReviva Pharmaceuticals Holdings Inc.April 12, 2026 | barrons.comReviva Pharmaceuticals Holdings (RVPH) price target increased by 2,046.68% to 117.30March 27, 2026 | msn.comAnalysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock SplitMarch 25, 2026 | finance.yahoo.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVPHW CIK1742927 WebN/A Phone408-501-8881FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RVPHW) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.